J004 Darbepoetin-<alpha> protects heart against ischemia-reperfusion: role of BCL-2 family proteins  by Schlecht-Bauer, D. et al.
Abstracts S103
investigate the contribution of the cAMP-binding protein Epac 
(Exchange protein directly activated by cAMP) in the regulation 
of the contractile properties of rat ventricular cardiac myocytes. 
We report that both PKA and Epac increased cardiac sarcomere 
contraction but through opposite mechanisms. Differently 
from PKA, selective Epac activation by the cAMP analog 8-pCPT 
reduced Ca2+ transient amplitude and increased cell shortening 
in intact cardiomyocytes as well as myo lament Ca2+ sensitivity 
in permeabilized cardiomyocytes. Moreover, ventricular myocytes, 
which were infected in vivo with a constitutively active form of 
Epac, showed enhanced myo lament Ca2+ sensitivity compared to 
control cells infected with GFP alone. At the molecular level, Epac 
increased phosphorylation of two key sarcomeric proteins, cardiac 
Troponin I (cTnI) and cardiac Myosin Binding Protein-C (cMyBP-C). 
The effects of Epac activation on myo lament Ca2+ sensitivity and 
on cTnI and cMyBP-C phosphorylation were independent of PKA, 
and were blocked by protein kinase C (PKC) and Ca2+ calmodulin 
kinase II (CaMKII) inhibitors. Altogether these  ndings identify Epac 
as a new regulator of myo lament function.
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Recent reviews have concluded that although drug eluting stent 
(DES) are ef cient in reducing in stent restenosis, their use does not 
have a signi cant effect on overall long-term survival as compared 
with bare metal stent. DES is associated with delayed vascular 
wall healing and endothelial function restoration, which mandates 
longer-term dual antiplatelet therapy. Recent studies demonstrated 
that the microsatellite polymorphism in the promoter of heme 
oxygenase-1 (HO-1) gene is related to angiographic restenosis. 
HO-1 is a rate-limiting enzyme in heme degradation ; leading to 
the generation of free iron, biliverdin, and carbon monoxide (CO). 
HO-1 is recognized to offer protection in many cardiovascular 
disorders. We aim to assess the potential protective effect of 
hemin, a potent HO-1 inducer, in the development of ISR in both 
rat and hypercholesterolemic rabbit.
In a rat model of aorta stenting and rabbit iliac stenting, chronic 
treatment with hemin (50 mg/kg/48h/ip) reduced neointima growth 
(-30 % and -50 % in hemin-treated rats and rabbits respectively), 
and most importantly stent struts remained covered, contrarily 
to the use of sirolimus eluting stent. Analysis of the cells facing 
the arterial lumen (electron microscopy) revealed an ultra-
structure similar to endothelial cells and the expression of CD31 
(immunogold labeling). Endothelial coverage was similar in hemin-
treated rats and greater in hemin-treated rabbits when compared 
to their control groups. Analysis of protein expression, in rats, 
revealed that hemin, limited the early in ammatory, apoptotic 
and proliferative cellular events common to ISR. More particularly, 
hemin treatment was associated with a decrease activity of key 
regulators of smooth muscle cell migration and proliferation, 
p42/44, RhoA and an increase of the expression of both cyclin 
dependent kinase inhibitors, p21 andp27kip1. This bene cial effect 
of hemin was abolished in presence of SnPP, an inhibitor of HO-1. 
Finally, CORM-3, a speci c carbon monoxide donor, limited ISR.
In conclusion, hemin reduced neointima growth without 
compromising re-endothelialization of the stented arteries. HO-1 
plays important role in limiting neointima growth, at least through 
the production of CO, and can be regarded as a new therapeutic 
target to prevent ISR.
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Heart can usually survive a short period of ischemia, but when this 
period is too long, damages of the cardiac tissue became irreversible 
and are possibly exacerbated by blood reperfusion. Loss of cardiac 
myocytes via apoptosis is believed to contribute to the continuous 
decline of ventricular function described in heart failure. Limiting 
theses deleterious responses is of major importance in cardiac surgery 
and for the treatment of coronary thrombosis. The purpose of this 
study was to assess the short and long term cardioprotective effects 
of the long lasting effect erythropoietin analogue darbepoetin-α (DA) 
in a myocardial ischemia-reperfusion model in rat and ; to investigate 
the signaling pathway through which DA potentially limits apoptosis 
of cardiomyocytes.
Rat were subjected to 40 min left coronary artery ligation followed 
by 3h, 72 h or 4 weeks reperfusion and they received either DA 
(3 or 30 g/kg) or vehicle i.v. prior ischemia. Left ventricle (LV) 
function was assessed by echocardiography prior surgery and after 
reperfusion. Hearts were collected for histological analysis, protein 
analysis and reactive oxygen species (ROS) production.
In DA3 and DA30 72hrs groups, both LV shortening fraction and 
LV ejection fraction were higher vs. control (P<0.05), matching 
with histological analysis revealing a relative LV infarct size 72h 
post ischemia of 40 ± 5 % in control vs. 27 ± 3 and 17 ± 2 % in DA3 
and DA30, respectively. DA treatment lowered ROS production, 
the activity of caspase 3 in 3h and 72h reperfusion groups, and 
activated the JAK2/AkT signaling pathway and then increased both 
phosphorylated Bad and GSk3β proteins. This was consistent with 
the decrease of Bad-Bcl-Xl in DA30 group, suggesting an increased 
level of Bcl-Xl protein. Similar results were obtained in DA-treated 
rats reperfused 4 weeks ; in which cardiac  brosis was signi cantly 
lower than that in control group.
DA pre-treatment limited in a dose dependent manner the early 
and late I/R-induced heart injury in rat. Anti-apoptotic effects 
mediated through the activation the survival kinase Akt that 
regulates the Bcl-2 family proteins and activates GSK-3β is central 
in the DA cardioprotective mechanism.
